NCAM1 and diffuse large B-cell lymphoma: NK cells, marked by CD16+CD56+, did not show significant differences between early and late-stage or high-risk and low-risk groups, suggesting that NK cells may play a relatively limited role in the immune landscape of DLBCL in this cohort.